Denise Ricigliano, NP
Nurse Practitioner · Salinas, CANPI 1073763835
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,300 of the $10,251 with a category attached, or 61.5%. 24 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 53.8% of the total. Reporting peaked in 2023 at $5,996 and has fallen 80.6% since, to $1,165 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $99.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$6K
- Myriad Women's Health, Inc.$1K
- Johnson & Johnson$613
- Merck$275
- Novartis$274
- E.r. Squibb & Sons, L.L.C.$243
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$6,30061%
- Food & beverage$3,69836%
- Education$2532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 21 | $5,512 |
| Myriad Women's Health, Inc. | 2 | $1,200 |
| Johnson & Johnson | 7 | $613 |
| Merck | 10 | $275 |
| Novartis | 14 | $274 |
| E.r. Squibb & Sons, L.L.C. | 3 | $243 |
| Amgen | 6 | $232 |
| GSK | 4 | $191 |
| AbbVie | 3 | $167 |
| Genentech, Inc. | 2 | $158 |
| AstraZeneca | 7 | $155 |
| ADC Therapeutics America, Inc. | 1 | $145 |
| Daiichi Sankyo Inc. | 5 | $139 |
| Lilly USA, LLC | 3 | $138 |
| Seagen Inc. | 5 | $132 |
| Genmab U.S., Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $123 |
| Eisai Inc. | 2 | $118 |
| Exelixis Inc. | 1 | $112 |
| Incyte Corporation | 1 | $99 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $39 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,251 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 19 | $527 |
| Lorazepam | 15 | $50 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Salinas
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.